PROCLAIM-CX-072: A First-in-Human Trial to Assess Tolerability of the Protease-Activatable Anti–PD-L1 Probody™ CX-072 in Solid Tumors and Lymphomas

Alexander I. Spira, Mark R. Middleton, Aung Naing, Karen A. Autio, John J. Nemunaitis, Johanna C. Bendell, Michael Gordon, Rachel W. Humphrey, Chihunt Wong, Naiyer A. Rizvi. Poster presented at ASCO 2017, June 2-6, Chicago, Illinois.